We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK to License Arrowhead’s RNAi Therapeutic for Liver Disease in $1 Billion Deal
GSK to License Arrowhead’s RNAi Therapeutic for Liver Disease in $1 Billion Deal
GlaxoSmithKline (GSK) has forged an exclusive license agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic currently in a phase 1/2 trial. The deal is potentially worth more than $1 billion.